References
- Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1–3. doi:10.1111/jdv.14386.
- Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919. doi:10.1080/1744666X.2019.1648209.
- Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis rook’s textbook of dermatology. Oxford: Blackwell Publishing Inc; 2008. p. 1731–1800.
- Ly K, Beck KM, Smith MP, et al. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42. doi:10.2147/PTT.S181808.
- Hoegler KM, John AM, Handler MZ, et al. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–1651. doi:10.1111/jdv.14949.
- Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13–19. doi:10.1007/s40257-021-00655-y.
- Morita A, Kotowsky N, Gao R, et al. Patient characteristics and burden of disease in japanese patients with generalized pustular psoriasis: results from the medical data vision claims database. J Dermatol. 2021;48(10):1463–1473. doi:10.1111/1346-8138.16022.
- Bernardo D, Thaçi D, Torres T. Spesolimab for the treatment of generalized pustular psoriasis. Drugs. 2024;84(1):45–58. doi:10.1007/s40265-023-01988-0.
- Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pusular psoriasis. Am J Clin Dermatol. 2002;23(Suppl 1):51–64. doi:10.1007/s40257-021-00658-9.
- Kamiya K, Ohtsuki M. Epidemiological survey of patients with pustular psoriasis in the japanese society for psoriasis research from 2017 to 2020. J Dermatol. 2023; Jan50(1):3–11. doi:10.1111/1346-8138.16583.
- Lu J, Huang D, Yang N, et al. Better efficacy, lower recurrence rate and decreased CD8 + TRM with guselkumab treatment for generalized pustular psoriasis: a prospective cohort study from China. Clin Immunol. 2024;259:109899. doi:10.1016/j.clim.2024.109899.
- Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. doi:10.1111/1346-8138.14294.